Cell therapy is a growing area of interest in clinical practice. Advances in cell therapy are increasing the number of options addressing a spectrum of challenging medical conditions. There has also been a corresponding increase in the number and types of methods for delivering these therapies to patients. Ideally, these devices should be cytocompatible, i.e., have minimal to no adverse impact on the cell therapy on delivery.
CytoGarde follows the guidelines delineated in ASTM F3206 – 17* in testing for recovery, viability and functionality of clinically relevant cell types.